close-icon

MHQ: Clinical IntelligencePowered by SurvivorNet

  • health-panel

    Health Panel

  • clinical-trial

    Clinical Trials

    ?
Prefer to talk instead of typing?
close-icon

Answers offered are informational and do not constitute medical advice. Learn more

close-icon
Health Profile

Enter health info to personalize results.

What is your gender?

What is your age?

close-icon
Clinical Trials

clinical-icon

filter

Clear List

Ask me anything about your health...

I’m listening

thinking

responding

close-icon close-icon
close-icon
close-icon
close-icon
left-icon Back to Results

Dr. Harold J. Burstein

ABOUT

Dr. Burstein is an internationally renowned breast cancer expert, who has led and participated in multiple clinical trials, and developed national and international breast cancer treatment guidelines.

Dr. Harold J. Burstein profile image

Published Articles

Lessons From the SONIA Trial on Timing of CDK4/6 Inhibitors in Advanced Breast Cancer-The Sooner, the Better?- 2026 Feb 19
Correction: Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer.- 2026 Feb 18
Outcomes of patients with de novo oligometastatic breast cancer treated with curative intent at a single institution.- 2026 Jan 8
NCCN Guidelines® Insights: Breast Cancer, Version 5.2025.- 2025 Nov
Long-term outcomes with adjuvant CDK4/6 inhibitors: who benefits most?- 2026 Feb
Tailoring treatment to cancer risk and patient preference: the 2025 St Gallen International Breast Cancer Consensus Statement on individualizing therapy for patients with early breast cancer.- 2025 Dec
Prognostic value of patient-reported depression in women with hormone-responsive early breast cancer in TEXT and SOFT.- 2025 Oct 1
Circulating Tumor Cell Dynamics after CDK4/6 Inhibitor for Hormone Receptor-Positive Metastatic Breast Cancer: A Biomarker Analysis from the PACE Phase II Study.- 2025 Nov 3
Circulating tumor DNA mutational landscape and dynamics after progression on a CDK4/6 inhibitor in the PACE phase II trial for metastatic HR-positive/HER2-negative breast cancer.- 2025 Aug
Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer.- 2025 Jun

Clinical Trials

Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive
Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer
Bevacizumab With or Without Cyclophosphamide and Methotrexate: A Pilot Study in Women With Operable Breast Cancer
Bevacizumab in Combination With Vinorelbine and Trastuzumab for HER2-Positive, Metastatic Breast Cancer
Metronomic Low-Dose Cyclophosphamide and Methotrexate With or Without Bevacizumab in Treating Women With Metastatic Breast Cancer
Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer
Dose Dense Abraxane in Adjuvant Chemotherapy for Breast Cancer
Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider